AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01494155
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
Trial: NCT00215540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
Trial: NCT00760370
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg intravenous (iv), one treatment
Trial: NCT03831984
Drug: 0,09% Bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
Trial: NCT02696564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule per day for two weeks, followed by two capsules per day for 46 weeks
Trial: NCT03857568
Drug: SHR0410
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug will be dosed repeatedly
Trial: NCT03857568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dosed repeatedly
Trial: NCT00032890
Drug: glucosamine
RxNorm normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00032890
Drug: glucosamine and chondroitin sulfate combined
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00032890
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04605432
Drug: PEG-FFI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher.
Trial: NCT04605432
Drug: PEG-nonFFI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse.
Trial: NCT01313494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT00111371
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02479971
Drug: Clindamycin-gentamicin irrigation
RxNorm normalized name: gentamicin Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
Trial: NCT02604550
Drug: Percocet 7.5/325
RxNorm normalized name: Percocet 7.5/325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percocet 7.5/325 will taken as needed up to every four hours.
Trial: NCT01270386
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo p.o. once daily
Trial: NCT01931241
Drug: AHRO-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
Trial: NCT04447534
Drug: zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc tablets
Trial: NCT02938949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00570349
Drug: Nitric Oxide for Inhalation
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
Trial: NCT00570349
Drug: Nitric Oxide for Inhalation
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
Trial: NCT03830203
Drug: BAT1806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg
Trial: NCT03707639
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Trial: NCT01368107
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
Trial: NCT01021488
Drug: Rosuvastatin 20mg/d for 14days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
Trial: NCT01732471
Drug: Kuvan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
Trial: NCT03347344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg will be administered (per os) twice a day
Trial: NCT01870804
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01870674
Drug: YH12852
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01870674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01135069
Drug: Tretinoin microsphere 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of acne vulgaris
Trial: NCT01135069
Drug: Brand Retin-A Micro tretinoin microsphere gel 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of acne vulgaris
Trial: NCT01681316
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Trial: NCT02468128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
Trial: NCT01422135
Drug: AG200-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
Trial: NCT00574249
Drug: placebo (vehicle ointment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Trial: NCT00805090
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 37.5 mg
Trial: NCT04944303
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal doseage of normal saline was injected to reverse the NMB.
Trial: NCT03258424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-428 or placebo will be given QD for 14 days.
Trial: NCT00232596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT01953432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo daily dosing
Trial: NCT02648477
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01399606
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,10,20,or 40 mg per day, in a once daily scheme
Trial: NCT02674399
Drug: JointStem
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02674399
Drug: Synvisc-One
RxNorm normalized name: Synvisc-One 48mg/6ml Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02089529
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen/Ibumetin with no information, positive information and neutral information
Trial: NCT02089529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with no information, positive information and neutral information
Trial: NCT02544191
Drug: GnRHa/ hCG/ hMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
Trial: NCT03479892
Drug: NNC0194-0499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Trial: NCT03479892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly injections of NNC0194-0499 matched placebo.
Trial: NCT02978859
Drug: MGCD516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
Trial: NCT00955981
Drug: RDEA594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uricosuric agent for the treatment of gout
Trial: NCT00955981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02079636
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02437032
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with 150-300 UI recombinant FSH
Trial: NCT02437032
Drug: Urinary FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with 150-300 UI urinary FSH
Trial: NCT02437032
Drug: hMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation with 150-300 UI hMG
Trial: NCT00689559
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3480 capsules qd, oral, 22 days
Trial: NCT00689559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo qd, 12 days
Trial: NCT02099188
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m2/day - Powder for solution for infusion
Trial: NCT01275911
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
Trial: NCT01929161
Drug: Placebo (for oxytocin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal spray manufactured to mimic oxytocin nasal spray
Trial: NCT03762343
Drug: ultrasound guided Greater occipital nerve block
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
Trial: NCT04364113
Drug: Medications needed to maintain usual blood pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The MAP goal for the usual blood pressure group is \<=107 mm Hg for ages 18-60 and \<=113 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Trial: NCT01758198
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04806659
Drug: SH1573 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients from each cohort will be administered SH1573 capsules every day of 28-day treatment cycles until disease progression or unacceptable toxicities.
Trial: NCT02046083
Drug: arachid
RxNorm normalized name: arachidate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01524783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were treated with two tablets of matching placebo once daily orally taken.
Trial: NCT03035305
Drug: Seasonal malaria chemoprevention
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each round of SMC distribution (total of 4 rounds):~* For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~* For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine
Trial: NCT00733083
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection one injection in the beginning of anesthesia
Trial: NCT03663764
Drug: Thymosin a1
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
Trial: NCT00948506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical placebo
Trial: NCT03663764
Drug: concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .
Trial: NCT00356252
Drug: mixed carotenoids
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04627532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will recieve placebo
Trial: NCT00477607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
Trial: NCT01173055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given orally twice daily in tablet form at different times during the course of the study.
Trial: NCT01829178
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 420 mg in 3 divided dose plus standard chemotherapy
Trial: NCT01829178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets: 420 mg in 3 divided dose
Trial: NCT01829178
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
Trial: NCT03467763
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00003910
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
Trial: NCT00003910
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
Trial: NCT00704301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 times a day
Trial: NCT03844243
Drug: Isotonic-saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection
Trial: NCT01903785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01892345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
Trial: NCT01488708
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
Trial: NCT01488708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
Trial: NCT03427554
Drug: Tretinoin cream 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
Trial: NCT03427554
Drug: RETIN-A® Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RETIN-A® (Tretinoin) Cream (Valeant)
Trial: NCT03427554
Drug: Vehicle of the test product
RxNorm normalized name: The Magic Bullet Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
Trial: NCT00214825
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg daily for 6 weeks with placebo
Trial: NCT02407054
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02407054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02228395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm
Trial: NCT00312481
Drug: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
RxNorm normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
Trial: NCT01005303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Tablet Daily
Trial: NCT02741557
Drug: DTG/RPV FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
Trial: NCT01403285
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
Trial: NCT01294644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT01106807
Drug: CD07223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
Trial: NCT01106807
Drug: Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microliters Epiduo Gel on one of the half-face for the morning dose
Trial: NCT00234676
Drug: Premarin ®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin ® 0.625 mg per day orally
Trial: NCT01425398
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
Trial: NCT01425398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
Trial: NCT01319344
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg o.d. per os
Trial: NCT00378976
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily as per experimental drug